The acute biobank collection can support explorations of novel application of laboratory biomarkers in acute medical care. The population is acute medical presentations to secondary care. Examples of areas currently in exploration are acute cardiovascular presentations and acute kidney injury. The collection consists of whole blood, serum, plasma and citrate plasma samples and associated clinical data. The collection has scope for adjustment to the sample type collection through NCARC’s simple amendment process. This collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research in establishing a clear diagnosis in patients presenting to hospitals. There is potential to improve the method and time taken for diagnosis with refinement of laboratory processing and biomarker discovery. The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • Biomarker studies • Immunological studies • Multi-morbidity studies

NCARC has the following samples and data from approximately 60 patients with Idiopathic Inflammatory Myopathies (IIM), otherwise known as myositis. Samples: • EDTA whole blood – frozen – for subsequent DNA and plasma extraction • Tempus whole blood – frozen – for subsequent RNA extraction • Extracted serum – processed and frozen – for subsequent use • Muscle biopsy samples – For ‘fresh use’ or processed and frozen for subsequent use Data: • Diagnosis (including sub group – DM, PM, IBM) • Clinical features • Laboratory investigations • Past and current medications • Auto-antibody status • Muscle biopsy details • Manual Muscle Test • Disease activity assessment • Damage index • HAQ • Functionality index and quality of life index • Ethnicity • Month and year of birth • Month and year of disease onset This is a rare autoimmune condition that can affect the muscles and skin of sufferers and result in weakness and disability. The aim of this collection is to promote high quality biomedical research (through access to samples and data) to understand more about this particular disease and identify new ways to improve the diagnosis, treatment and care of patients with IIM. The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • Gene expression analysis • Biomarker discovery • Immunological and metabolomics studies • Multi-morbidity studies • Functional analysis of immune cells versus cancer cells

Motor neurone disease (MND) samples (blood, plasma and serum) are difficult to collect and in conjunction with clinical data that allows deep phototyping, we hope this collection can contribute to (but not limited to) robust biomarker discovery studies. MND is an uncommon condition that affects the brain and nerves. There is no cure for MND, but we do hope that this collection can promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research to reduce the impact it has on a person’s daily life by improving the diagnosis and treatment of MND. The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • Biomarker discovery • Drug discovery • Gene expression analysis • Neurogenesis and proteomics studies • Alzheimer’s & Dementia studies

This collection of cerebrospinal fluid, serum, plasma and whole blood samples from people with Spinal Muscular Atrophy (SMA) includes baseline samples prior to treatment and follow-up samples collected after commencement of medications such as nusinersen. SMA is a devastating neurological disease. Patients suffer from progressive wasting and weakness with a significant effect on quality of life, as well as an increase morbidity and mortality. Whilst genetic underpinnings of this disease is not yet determined. This collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research of why SMA occurs. These samples could be used to deepen our understanding of the cause of SMA, help understand why some patients are affected by the condition more than others and find biomarkers of early treatment response. The biological samples collected will enable a number of different analyses to be performed. This may include (but not limited to): • Biomarker studies • Immunological studies • Multi-morbidity studies • Functional analysis of cells

This is a new collection of serum, plasma and whole blood samples, with associated clinical data, from patients with Myasthenia Gravis. We aim to collect approximately 50 samples in 2022. The collection aims to include samples from people with myasthenia gravis who are newly diagnosed, stable on or off immunosuppression, experiencing disease exacerbation, and those refractory to standard treatment. Alongside collection of a minimum data-set including standardised outcome measures, this collection should become a valuable tool to researched looking to better understand the biochemical changes that occur in myasthenia of different sub-types, treatment-requirements and at disease activity. The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • Biomarker studies • Immunological studies • Multi-morbidity studies • Functional analysis of cells

The Covid-19 collection consists of blood, serum, saliva, sputum, nasal strips, nasopharyngeal & oropharyngeal swabs and pleural fluid from patients infected with the novel coronavirus. In some cases, longitudinal samples have and will be collected, which could include samples prior to or after infections with Covid-19. The Covid-19 collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research to answer a range of questions including: • How does Covid-19 make some people severely unwell? • Does our immune system protect us from re-infection with COVID-19 after we have recovered from infection? • How well do tests for Covid-19 work? • What are the best ways to identify or test for Covid-19? • How does the body respond throughout the course of infection, recovery and possible reinfection? • How long does our immune system protects us from re-infection with Covid-19 after we have recovered from infection? • How does the immune system contribute to long-term post viral symptoms? The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • The effects of long Covid-19 • Biomarker studies • Immunological studies • Multi-morbidity studies • Functional analysis of cells of the respiratory system

The vascular disease collection contains approximately 400 samples (blood, plasma and serum) with associated clinical data from patients pre and post bariatric surgery. The collection boasts up to 5 years of follow up data post-surgery that could be valuable when studying longer term outcomes post bariatric surgery. The vascular disease collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research to identify variables associated with vascular disease – long term occurrence of peripheral vascular disease, cardiovascular diseases, obesity. The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • Echocardiographic markers • Diabetes studies • Peripheral artery disease (PAD)

The respiratory collection has approximately 500 samples with associated clinical data. The collection includes samples of whole blood taken from adults who have respiratory or respiratory related conditions, but also includes other biological samples (plasma, sputum, broncho-alveolar lavage, pleural fluid, solid tissue). The respiratory collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research to improve the diagnosis and treatment of respiratory diseases, that is lung disease, including (but not limited to) inflammatory, obstructive and restrictive lung disorders, respiratory tract infections, pleural cavity disease, malignancies relating to the respiratory system and pulmonary vascular conditions. The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • Gene expression analysis • Biomarker discovery • Immunological studies • Multi-morbidity studies • Functional analysis of cells of the respiratory system

The respiratory collection has approximately 500 samples with associated clinical data. The collection includes samples of whole blood taken from adults who have respiratory or respiratory related conditions, but also includes other biological samples (plasma, sputum, broncho-alveolar lavage, pleural fluid, solid tissue). The respiratory collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research to improve the diagnosis and treatment of respiratory diseases, that is lung disease, including (but not limited to) inflammatory, obstructive and restrictive lung disorders, respiratory tract infections, pleural cavity disease, malignancies relating to the respiratory system and pulmonary vascular conditions. The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): • Gene expression analysis • Biomarker discovery • Immunological studies • Multi-morbidity studies • Functional analysis of cells of the respiratory system